FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Только для исследовательских целей. Полный disclaimer →

Библиотека стаков

Body Recomp Stack

Fat Lossintermediate

86

синергия

86
Share
Пептиды

3

Среднедневная дозировка мкг

1,100

Уровень

intermediate

Добавлено

May 17, 2026

Обзор

The Body Recomp Stack is designed for simultaneous muscle building and fat reduction — the "have it all" protocol that combines GH axis optimization with recovery support. It pairs the proven CJC-1295 + Ipamorelin GH stack with BPC-157 to support the connective tissue, joints, and recovery that intensive body recomposition training demands. CJC-1295 and Ipamorelin drive the anabolic and lipolytic effects of elevated GH — increased protein synthesis, improved fat metabolism, better sleep quality, and enhanced recovery capacity. The GH axis improvements are particularly powerful for body recomposition because GH drives lipolysis (fat breakdown for energy) while also supporting lean tissue preservation and growth. BPC-157 addresses the structural demands of the training required for recomposition. Heavy lifting and high-volume training place significant stress on tendons, ligaments, and joints — the connective tissue structures that most often limit training consistency. BPC-157''s localized healing effects keep these structures healthy during progressive overload, allowing users to train harder and more consistently without injury interruptions. The practical outcome: GH optimization drives the hormonal environment for simultaneous fat loss and muscle gain, while BPC-157 keeps the body structurally sound enough to train at the intensities required to achieve that environment. Many athletes and clinicians consider this the most complete body composition protocol available without exogenous hormones.

Протокол дозирования

CJC-1295

Every day· subcutaneous

Читать больше о CJC-1295 →

300 mcg

на дозу

Ipamorelin

Every day· subcutaneous

Читать больше о Ipamorelin →

300 mcg

на дозу

BPC-157

Twice per day· subcutaneous

Читать больше о BPC-157 →

250 mcg

на дозу

Цели и доказательства

Simultaneous fat loss and muscle gainTraining recoveryBody compositionJoint health
Уровень доказательств:Исследования на животных

Предупреждения

  • BPC-157 was removed from the FDA Category 2 list (April 2026) but remains under PCAC review (July 23, 2026) — removal is not approval; not legal to compound yet.

Comments

Sign in to join the discussion

Уведомление: Этот стак представлен сообществом и предназначен для исследовательских целей только. Peptide Contacts не проверяет безопасность или эффективность представленных стаков. Всегда проконсультируйтесь с квалифицированным медицинским специалистом перед использованием любого протокола пептидов.